Eagle Pharmaceuticals In-Licenses US Rights For Emergency Hospital Product, Q2 Earnings Beat Consensus

  • Eagle Pharmaceuticals Inc EGRX has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH for the commercial rights to its product, Landiolol, in the U.S. 
  • Landiolol, a hospital emergency use product, is approved in Europe to treat non-compensatory sinus tachycardia and tachycardic supraventricular arrhythmias. 
  • Eagle will support the submission of marketing to the FDA seeking approval for Landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter.
  • Landiolol is a short-acting, ultra-high selective beta-1 adrenoceptor blocker developed by AOP Orphan. 
  • Under the agreement terms, Eagle will make an upfront payment of $5 million, followed by additional payments upon regulatory approval(s) and based upon commercial sales. 
  • EGRX has reported Q2 revenue of $48.1 million, +14.8%, beating the consensus of $45.86 million.
  • The increase primarily reflects higher product sales of Belrapzo and Ryanodex, partially offset by lower product sales of Bendeka.
  • Q2 adjusted EPS of $0.95 surpassed the consensus of $0.80.
  • As of June 30, 2021, Eagle held $108.7 million in cash and cash equivalents plus $52.7 million in net accounts receivable. The Company had $30 million in outstanding debt.
  • Eagle expects approximately $20 million - $25 million from combined royalty and milestone revenue next year for Treakisym (bendamustine) if Treakisym RI formulation is approved.
  • Price Action: EGRX shares are up 4.54% at $47.85 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLong IdeasNewsGuidanceHealth CareContractsSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!